LONDON, UK I1, 2024 I Vicebio Ltd ("Vicebio"), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory ...

BOSTON, MA, USA I, 2024 I LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally ...

NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - ...

MELBOURNE, Australia I November 19, 2024 I Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative ...

HAYWARD, CA, USA I1, 2024 I Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first ...

OXFORD, UK I November 19, 2024 I Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, ...

AURORA, CO, USA I November 21, 2024 I OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced today the closing of a Series A extension financing led by existing ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of ...

Collaboration will combine Vyriad's lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ...

MELBOURNE, Australia I 19, 2024 I Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its ...

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection ...